FINWIRES · TerminalLIVE
FINWIRES

$APLS

4 stories mentioning APLS

Every FINWIRES story that references APLS, newest first.

Research

Update: Mizuho Securities Keeps Price Target on Apellis Pharmaceuticals to $41, Maintains Neutral Rating

(Updated to keep price target unchanged).Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Wire

Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Wire

Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says

Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.The company is scheduled to report its Q1 financial results on April 29.Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).Oppenheimer has an outperform rating on the stock and a $275 price target.Price: $190.50, Change: $+4.55, Percent Change: +2.44%

$APLS$BIIB
Research

Wells Fargo Downgrades Apellis Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $41 From $26

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$APLS